Clinical trial
Study of AP23573 in Patients With Relapsed or Refractory Hematologic…
NCT00086125 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00086125 |
|---|---|
| Title | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) |
| Official title | A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia, Lymphoma |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 57 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Jun 28, 2004 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: